Cargando…

Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention

Aims: Soluble suppression of tumorigenicity 2 (sST2) was validated to independently predict prognosis for heart failure (HF) and ST-segment elevation myocardial infarction (STEMI). In this study, we aimed to evaluate the relation between sST2 and coronary artery stenosis, and no-reflow phenomenon an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qinyao, Hu, Meirong, Ma, Shumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629709/ https://www.ncbi.nlm.nih.gov/pubmed/33551392 http://dx.doi.org/10.5551/jat.59832

Ejemplares similares

New R(2)-CHA(2)DS(2)-VASc score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention
por: Zhang, Qinyao, et al.
Publicado: (2022)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Somuncu, Mustafa Umut, et al.
Publicado: (2019)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Qi, Qi, et al.
Publicado: (2018)

Utility of Hematological Parameters in Predicting No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
por: Wang, Zuoyan, et al.
Publicado: (2018)

RDW as A Predictor for No-Reflow Phenomenon in DM Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Sun, Ying, et al.
Publicado: (2023)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
por: Badran, Hala Mahfouz, et al.
Publicado: (2020)

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention
por: Yang, Xiheng, et al.
Publicado: (2022)

MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Zhang, Xin-Tao, et al.
Publicado: (2022)

The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
por: Grancini, Luca, et al.
Publicado: (2023)

Association between the No-Reflow Phenomenon and Soluble CD40 Ligand Level in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Tascanov, Mustafa Begenc, et al.
Publicado: (2019)

Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction
por: Mazhar, Jawad, et al.
Publicado: (2015)

New CHA(2)DS(2)-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
por: Zhang, Qin-Yao, et al.
Publicado: (2020)

The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction
por: Bolayır, Hasan Ata, et al.
Publicado: (2017)

Incidence, Predictors, and Prognosis of Coronary Slow-Flow and No-Reflow Phenomenon in Patients with Chronic Total Occlusion Who Underwent Percutaneous Coronary Intervention
por: Wang, Yong, et al.
Publicado: (2020)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

Effect of chronic pretreatment with beta-blockers on no-reflow phenomenon in diabetic patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Al-Jabari, Ali Mohammed Kareem, et al.
Publicado: (2017)

Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis
por: Niu, Xiaowei, et al.
Publicado: (2018)

No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case–control study (NORM PPCI)
por: Rossington, Jennifer Ann, et al.
Publicado: (2020)

Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Refaat, Hesham, et al.
Publicado: (2021)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention
por: Deng, Lianxiang, et al.
Publicado: (2022)

A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2021)

Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention
por: Chang, Shu-min, et al.
Publicado: (2022)

Predicting coronary no-reflow in patients with acute ST-segment elevation myocardial infarction using Bayesian approaches
por: Zhang, Dongfeng, et al.
Publicado: (2014)

CHA(2)DS(2)-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention
por: Huang, Xin, et al.
Publicado: (2021)

Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention
por: Abdi, Seifollah, et al.
Publicado: (2015)

hsCRP and ET-1 expressions in patients with no-reflow phenomenon after Percutaneous Coronary Intervention
por: Liu, Min, et al.
Publicado: (2017)

Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts
por: Hashemi-Jazi, Mohammad, et al.
Publicado: (2017)

CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention
por: Mirbolouk, Fardin, et al.
Publicado: (2018)

Non-pharmaco, non-invasive management of coronary no-reflow phenomenon
por: Sinha, Santosh Kumar, et al.
Publicado: (2020)

Growth Differentiation Factor 15 as a Predictor of the No-Reflow Phenomenon in Patients with ST-Segment Elevation Myocardial Infarction
por: Kożuch, Marcin, et al.
Publicado: (2022)

CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Rashed, Mohamed Ismail, et al.
Publicado: (2022)

Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention
por: Yaylak, Barış, et al.
Publicado: (2018)

Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers
por: Shemirani, Hassan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nkeo06vobc37efrv6h0jr2e4f7